BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nahta R. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem 2012;19:1065-75. [PMID: 22229414 DOI: 10.2174/092986712799320691] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Keck S, Glencer AC, Rugo HS. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncology 2012;8:1383-96. [DOI: 10.2217/fon.12.143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
2 Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med 2015;12:342-54. [PMID: 26779371 DOI: 10.7497/j.issn.2095-3941.2015.0089] [Cited by in F6Publishing: 75] [Reference Citation Analysis]
3 Wu G, Li L, Qiu Y, Sun W, Ren T, Lv Y, Liu M, Wang X, Tao H, Zhao L, Cao J, He L, Li H, Gu H. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer. Acta Biochim Biophys Sin (Shanghai) 2021;53:1625-39. [PMID: 34586349 DOI: 10.1093/abbs/gmab141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Campone M, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, Arnedos M, Loussouarn D, Wang Q, Vanlemmens L, Jimenez M, Rios M, Diéras V, Leroux A, Paintaud G, Rezai K, André F, Lion M, Merlin JL. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). Eur J Cancer 2021;158:169-80. [PMID: 34678678 DOI: 10.1016/j.ejca.2021.09.017] [Reference Citation Analysis]
5 Kaymak A, Sayols S, Papadopoulou T, Richly H. Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance. Oncotarget 2018;9:28666-90. [PMID: 29983888 DOI: 10.18632/oncotarget.25596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu Y, Hu Z. Identification of collaborative driver pathways in breast cancer. BMC Genomics 2014;15:605. [PMID: 25034939 DOI: 10.1186/1471-2164-15-605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda J, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells. Breast Cancer Res Treat 2017;166:55-68. [DOI: 10.1007/s10549-017-4382-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
8 Yang R, Bai Y, Qin Z, Yu T. EgoNet: identification of human disease ego-network modules. BMC Genomics 2014;15:314. [PMID: 24773628 DOI: 10.1186/1471-2164-15-314] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
9 Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154-166. [PMID: 25057302 DOI: 10.1177/1758834014530023] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 24.6] [Reference Citation Analysis]
10 Raphael J, Desautels D, Pritchard KI, Petkova E, Shah PS. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer 2018;91:38-46. [DOI: 10.1016/j.ejca.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
11 Nahta R. New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012;4:53-64. [PMID: 23869176 DOI: 10.2147/BCTT.S24976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ma F, Zhu W, Guan Y, Yang L, Xia X, Chen S, Li Q, Guan X, Yi Z, Qian H, Yi X, Xu B. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget 2016;7:66020-31. [PMID: 27602761 DOI: 10.18632/oncotarget.11791] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
13 Chuang TC, Wu K, Lin YY, Kuo HP, Kao MC, Wang V, Hsu SC, Lee SL. Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. Environ Toxicol 2021;36:737-47. [PMID: 33325633 DOI: 10.1002/tox.23076] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Schwartzberg LS, Vidal GA. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. Clin Breast Cancer 2020;20:e439-49. [PMID: 32278641 DOI: 10.1016/j.clbc.2020.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014;12:132. [PMID: 25285786 DOI: 10.1186/s12916-014-0132-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
16 Carrella D, Manni I, Tumaini B, Dattilo R, Papaccio F, Mutarelli M, Sirci F, Amoreo CA, Mottolese M, Iezzi M, Ciolli L, Aria V, Bosotti R, Isacchi A, Loreni F, Bardelli A, Avvedimento VE, di Bernardo D, Cardone L. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. Oncotarget 2016;7:58743-58. [PMID: 27542212 DOI: 10.18632/oncotarget.11318] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
17 Koren J 3rd, Miyata Y, Kiray J, O'Leary JC 3rd, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PLoS One 2012;7:e35566. [PMID: 22563386 DOI: 10.1371/journal.pone.0035566] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
18 Zhang H, Xu HL, Wang YC, Lu ZY, Yu XF, Sui DY. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. Int J Mol Sci 2018;19:E1053. [PMID: 29614812 DOI: 10.3390/ijms19041053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
19 Ren J, Wang B, Li J. Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer. BMC Syst Biol 2018;12:130. [PMID: 30577793 DOI: 10.1186/s12918-018-0646-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Nicolini A, Barak V, Biava P, Ferrari P, Rossi G, Carpi A. The Use of Immunotherapy to Treat Metastatic Breast Cancer. Curr Med Chem 2019;26:941-62. [PMID: 29424297 DOI: 10.2174/0929867325666180209124052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
21 Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev 2017;59:1-21. [PMID: 28715775 DOI: 10.1016/j.ctrv.2017.06.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
22 Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol 2013;190:5588-99. [PMID: 23630363 DOI: 10.4049/jimmunol.1203216] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
23 Gupta P, Srivastava SK. HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol Oncol 2014;8:1532-47. [PMID: 24994678 DOI: 10.1016/j.molonc.2014.06.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
24 Franco-gonzalez JF, Ramos J, Cruz VL, Martinez-salazar J. Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field. J Comput Aided Mol Des 2014;28:1093-107. [DOI: 10.1007/s10822-014-9787-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. Mol Med Rep 2017;15:2957-68. [PMID: 28358430 DOI: 10.3892/mmr.2017.6415] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
26 Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer 2017;17:646. [PMID: 28899363 DOI: 10.1186/s12885-017-3641-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
27 Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int J Cancer 2020;147:266-76. [PMID: 31904863 DOI: 10.1002/ijc.32859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wong DJ, Hurvitz SA. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014;2:122. [PMID: 25568875 DOI: 10.3978/j.issn.2305-5839.2014.08.13] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
29 Tong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X, Shen K. IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. Front Oncol 2020;10:550. [PMID: 32391265 DOI: 10.3389/fonc.2020.00550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lee SO, Lee MH, Lee KR, Lee EO, Lee HJ. Fomes fomentarius Ethanol Extract Exerts Inhibition of Cell Growth and Motility Induction of Apoptosis via Targeting AKT in Human Breast Cancer MDA-MB-231 Cells. Int J Mol Sci 2019;20:E1147. [PMID: 30845749 DOI: 10.3390/ijms20051147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract 2012;2012:648965. [PMID: 22830017 DOI: 10.1155/2012/648965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
32 Lazaro G, Smith C, Goddard L, Jordan N, Mcclelland R, Barrett-lee P, Nicholson RI, Hiscox S. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine-Related Cancer 2013;20:691-704. [DOI: 10.1530/erc-13-0019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
33 Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis G, Skondra M, Chrisafi S, Koutras A, Bafaloukos D, Razis E, Papadopoulou K, Papakostas P, Kalofonos HP, Pectasides D, Skarlos P, Kalogeras KT, Fountzilas G. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. Cancer Genomics Proteomics 2018;15:461-71. [PMID: 30343280 DOI: 10.21873/cgp.20105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, Buchholz CJ. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 2013;21:109-18. [PMID: 22968478 DOI: 10.1038/mt.2012.186] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 8.5] [Reference Citation Analysis]
35 Parakh S, King D, Gan HK, Scott AM. Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results Cancer Res 2020;214:1-70. [PMID: 31473848 DOI: 10.1007/978-3-030-23765-3_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis 2017;6:e385. [PMID: 28991258 DOI: 10.1038/oncsis.2017.86] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
37 Theile D, Lenz G, Momand JA, Kane SE. Resistance to HER2-Targeted Therapy. In: Prosperi JR, editor. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing; 2017. pp. 35-88. [DOI: 10.1007/978-3-319-70142-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
38 Spirina LV, Kondakova IV, Tarasenko NV, Slonimskaya EM, Usynin EA, Gorbunov AK, Yurmazov ZA, Chigevskaya SY. [Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--
AKT/m-TOR Pathway and Resistance to Cancer Therapy]. Zhongguo Fei Ai Za Zhi 2018;21:63-6. [PMID: 29357975 DOI: 10.3779/j.issn.1009-3419.2018.01.09] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Aziz SW, Aziz MH. Major Signaling Pathways Involved in Breast Cancer. In: Ahmad A, editor. Breast Cancer Metastasis and Drug Resistance. New York: Springer; 2013. pp. 47-64. [DOI: 10.1007/978-1-4614-5647-6_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Peiris D, Spector AF, Lomax-Browne H, Azimi T, Ramesh B, Loizidou M, Welch H, Dwek MV. Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors. Sci Rep 2017;7:43006. [PMID: 28223691 DOI: 10.1038/srep43006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
41 Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. J Cancer Res Clin Oncol 2019;145:821-8. [PMID: 30603906 DOI: 10.1007/s00432-018-02833-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Nahta R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol 2012;2012:428062. [PMID: 23227361 DOI: 10.5402/2012/428062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
43 Gupta P, Srivastava SK. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget 2014;5:1812-28. [PMID: 24729020 DOI: 10.18632/oncotarget.1743] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
44 Vanderhoeven F, Redondo AL, Martinez AL, Vargas-Roig LM, Sanchez AM, Flamini MI. Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells. Oncotarget 2018;9:26527-42. [PMID: 29899874 DOI: 10.18632/oncotarget.25480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
45 Fedele P, Ciccarese M, Surico G, Cinieri S. Pharmacotherapeutic options for patients with refractory breast cancer. Expert Opinion on Pharmacotherapy 2019;20:851-61. [DOI: 10.1080/14656566.2019.1574751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8:961-987. [PMID: 22894670 DOI: 10.2217/fon.12.95] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
47 Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, Rahman KM. 3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PLoS One 2013;8:e54657. [PMID: 23372748 DOI: 10.1371/journal.pone.0054657] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
48 Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med. 2012;18:1473-1479. [PMID: 23196784 DOI: 10.2119/molmed.2012.00302] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
49 Peake BF, Nahta R. Resistance to HER2-targeted therapies: a potential role for FOXM1. Breast Cancer Manag. 2014;3:423-431. [PMID: 25598845 DOI: 10.2217/bmt.14.33] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
50 Beck JT. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer. Onco Targets Ther 2015;8:3629-38. [PMID: 26675495 DOI: 10.2147/OTT.S88037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]